口服LfcinB通过改善肠道屏障和微生物群来缓解DSS诱导的大肠炎
Zhineng Liu1, Xinyun Qin1, Keyi Nong1
1College of Tropical Agriculture and Forestry, Hainan University, Danzhou 571737, China. 007zhanghaiwen@163.com.
Food & function
|January 31, 2024
概括
通过减少炎症和恢复肠道细菌,LfcinB的使用改善了小鼠的性结肠炎 (UC). 这项研究提供了LfcinB作为炎症性肠病的潜在治疗方法的证据.
科学领域:
- 胃肠道学和免疫学
- 微生物学 微生物学
- 类治疗药物 类治疗药物
背景情况:
- 性结肠炎 (UC) 是一种慢性炎症性肠病 (IBD),有效治疗方法有限.
- 牛乳酸衍生LfcinB具有抗菌和抗炎性质.
- 关于LfcinB在治疗大肠炎模型中的有效性,研究有限.
研究的目的:
- 为了研究口服LfcinB对小鼠中硫酸 (DSS) 诱导的UC的治疗效果.
- 评估LfcinB对结肠组织完整性,炎症和肠道微生物群组成的影响.
主要方法:
- 在小鼠中诱导了性结肠炎,使用饮用水中2.5%的DSS.
- 在接受治疗的组中,LfcinB是口服的.
- 分析了结肠组织的损伤,炎症细胞透和紧结蛋白表达.
- 评估了NF-κB/MAPK信号通路和肠道微生物组成.
主要成果:
- 口服LfcinB改善了结肠组织损伤,减少了炎症细胞透.
- LfcinB增加了紧结蛋白的表达,增强了肠道屏障的功能.
- LfcinB降低了炎症信号通路 (NF-κB/MAPK) 的调节,并抑制了致病细菌 (Bacteroides,Barnesiella,Escherichia).
结论:
- 口服LfcinB有效地缓解了小鼠的DSS诱导的性结肠炎.
- LfcinB的治疗作用与炎症信号通路的调节和肠道微生物组成有关.
- 作为UC治疗的潜在治疗剂,LfcinB显示出希望.
相关概念视频
Drugs for Treatment of Constipation-Predominant IBS
169
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
169
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
334
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
334
Drugs for Treatment of Diarrhea-Predominant IBS
175
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
175
Drugs for Treatment of Ulcerative Colitis in IBD
141
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
141


